Catalyst Pharmaceuticals Q4 Earnings Beat, Firdapse Revenues Rise Y/Y
Catalyst Pharmaceuticals(US:CPRX) ZACKS·2026-02-26 16:11Key Takeaways CPRX beat Q4 estimates with 68 cent EPS and $152.6M in revenues, up 8% year over year.Firdapse sales rose 18% to $97.6M, while Agamree revenues jumped 68% in the quarter.2026 revenue guidance of $615M-$645M reflects growth in Firdapse and Agamree sales.Catalyst Pharmaceuticals (CPRX) reported adjusted earnings of 68 cents per share for the fourth quarter of 2025, beating the Zacks Consensus Estimate of 42 cents. The company had recorded adjusted earnings of 70 cents in the year-ago quarter.Tot ...